Clinical Trial Update: HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy [Phase 3]

View source ↗

Summary

This clinical trial update reports on the Phase 3 HELIOS-B study evaluating vutrisiran for transthyretin amyloidosis with cardiomyopathy; results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloidosis with Cardiomyopathy

Drugs mentioned

• AMVUTTRA (VUTRISIRAN)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-21